Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: A multicenter clinical trial

Oncologist

Volumn 11, Issue 7, 2006, Pages 841-848

  Cartenì, Giacomo ^a   Bordonaro, Roberto ^b   Giotta, Francesco ^c   Lorusso, Vito ^c   Scalone, Simona ^d   Vinaccia, Vincenza ^e   Rondena, Roberta ^e   Amadori, Dino ^f  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c Istituto Oncologico   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e Respiratory Clinical Research   (Italy)

^f MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; ASTHENIA; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEVER; HEADACHE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; MAJOR CLINICAL STUDY; NAUSEA; ORTHOPEDIC SURGERY; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION; STATISTICAL ANALYSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33746658770     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-7-841     Document Type: Article

References (17)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001;27:165-176.
3. Domchek SM, Younger J, Finkelstein DM et al. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000;89:363-368.
4. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-1791.
5. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 1999;17:846-854.
6. Kohno N, Aogi K, Minami H et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005;23:3314-3321.
7. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-4057. Erratum in J Clin Oncol 2004;22:1351.
8. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. The Oncologist 2004;9(suppl 4):28-37.
9. Coleman RE. Bisphosphonates: clinical experience. The Oncologist 2004;9(suppl 4):14-27.
10. Theriault RL. Zoledronic acid (Zometa®) use in bone disease. Expert Rev Anticancer Ther 2003;3:157-166.
11. Lipton A. Treatment of skeletal complications in cancer patients: focus on bisphosphonates . Oncology Special Edition 2004;7:59-64.
12. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-1744.
13. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-1594.
14. Weinfurt KP, Li Y, Castel LD et al. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2002;13(suppl 5):180.
15. Rosen LS, Gordon DH, Dugan W Jr et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36-43.
16. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
17. Weinfurt KP, Castel LD, Li Y et al. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004;42:164-175.